{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:12:54Z","timestamp":1787238774700,"version":"build-2736575974"},"reference-count":25,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T00:00:00Z","timestamp":1744675200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Treatment of infections in patients with burn injuries is challenging due to altered antimicrobial pharmacokinetics. Continuous infusion \u03b2\u2010lactam therapy may be a useful antimicrobial stewardship strategy to improve pharmacodynamic target attainment in this population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case Summaries<\/jats:title>\n                    <jats:p>\n                      This report highlights the use of continuous infusion ceftolozane\/tazobactam (C\/T) in two patients with extensive total body surface area (TBSA) burns, suspected augmented renal clearance (ARC), and bloodstream infections caused by\n                      <jats:italic>Pseudomonas aeruginosa<\/jats:italic>\n                      with difficult\u2010to\u2010treat resistance (DTR\n                      <jats:italic>P. aeruginosa<\/jats:italic>\n                      ). Both patients received C\/T 9\u2009g\/day via continuous infusion. Minimum inhibitory concentrations (MIC) of C\/T were 8\/4 and 4\/4\u2009\u03bcg\/mL in Cases 1 and 2, respectively.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>\n                      Despite similar patient characteristics, average free plasma ceftolozane concentrations were 41.6\u2009mg\/L in Case 1 and 22.8\u2009mg\/L in Case 2. Measured free concentrations exceeded 4 times the MIC for 100% of each 24\u2010h infusion (\n                      <jats:italic>f<\/jats:italic>\n                      T\u2009&gt;\u20094xMIC), and bacteremia was successfully cleared in each case.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These cases highlight the variability of drug exposure in patients with extensive TBSA burn injuries and support continuous infusion \u03b2\u2010lactam therapy as a proactive strategy to optimize pharmacodynamic target attainment when pharmacokinetics are unpredictable.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/phar.70019","type":"journal-article","created":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T08:56:46Z","timestamp":1744707406000},"page":"386-392","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Pharmacokinetics of continuous infusion ceftolozane\/tazobactam in two patients with extensive total body surface area burns"],"prefix":"10.1002","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-4810-2145","authenticated-orcid":false,"given":"Jay D.","family":"Olivet","sequence":"first","affiliation":[{"name":"Department of Pharmacy UAB Hospital  Birmingham Alabama USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1545-7826","authenticated-orcid":false,"given":"Megan","family":"Amerson\u2010Brown","sequence":"additional","affiliation":[{"name":"Department of Pathology UAB Hospital  Birmingham Alabama USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0424-6721","authenticated-orcid":false,"given":"Juan J.","family":"Calix","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Infectious Diseases UAB Hospital  Birmingham Alabama USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5210-9778","authenticated-orcid":false,"given":"Emma","family":"Graffice","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Infectious Diseases UAB Hospital  Birmingham Alabama USA"},{"name":"University of Alabama at Birmingham Heersink School of Medicine  Birmingham Alabama USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyson","family":"Kilpatrick","sequence":"additional","affiliation":[{"name":"Department of Pharmacy UAB Hospital  Birmingham Alabama USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0990-0932","authenticated-orcid":false,"given":"Hanna F.","family":"Roenfanz","sequence":"additional","affiliation":[{"name":"Center for Anti\u2010Infective Research and Development Hartford Hospital  Hartford Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4148-0165","authenticated-orcid":false,"given":"David P.","family":"Nicolau","sequence":"additional","affiliation":[{"name":"Center for Anti\u2010Infective Research and Development Hartford Hospital  Hartford Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4464-3126","authenticated-orcid":false,"given":"Joseph L.","family":"Kuti","sequence":"additional","affiliation":[{"name":"Center for Anti\u2010Infective Research and Development Hartford Hospital  Hartford Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5346-0690","authenticated-orcid":false,"given":"Matthew L.","family":"Brown","sequence":"additional","affiliation":[{"name":"Department of Pharmacy UAB Hospital  Birmingham Alabama USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,4,15]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199529010-00003"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biotechadv.2018.11.013"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.37201\/req\/s01.13.2023"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00040-09"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciad428"},{"issue":"12","key":"e_1_2_10_7_1","first-page":"825","article-title":"Ceftolozane\/tazobactam: a new option in the treatment of complicated gram\u2010negative infections","volume":"39","author":"Sorbera M","year":"2014","journal-title":"P T"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2231"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/jbcr\/irad107"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens10020165"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2021.106299"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2505"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-024-04911-5"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2842"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-019-03573-4"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx221"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.106158"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics12071214"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01265-19"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200847100-00002"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/BCR.0000000000000147"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2017.09.019"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-200502000-00014"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2210"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00464-08"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkae089"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.70019","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T16:15:41Z","timestamp":1761063341000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1002\/phar.70019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,15]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["10.1002\/phar.70019"],"URL":"https:\/\/doi.org\/10.1002\/phar.70019","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,15]]},"assertion":[{"value":"2024-12-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}